Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
Ciancio A, Picciotto A, Giordanino C, Smedile A, Tabone M, Manca A, Marenco G, Garbagnoli P, Andreoni M, Cariti G, Calleri G, Sartori M, Cusumano S, Grasso A, Rizzi R, Gallo M, Basso M, Anselmo M, Percario G, Ciccone G, Rizzetto M, Saracco G. Ciancio A, et al. Among authors: manca a. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1079-86. doi: 10.1111/j.1365-2036.2006.03098.x. Aliment Pharmacol Ther. 2006. PMID: 16984502 Free article. Clinical Trial.
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G, Olivero A, Ciancio A, Carenzi S, Smedile A, Cariti G, Andreoni M, Orsi PG, Biglino A, Tabone M, Roffi L, Croce G, Manca A, Tappero G, Ciccone G, Rizzetto M. Saracco G, et al. Among authors: manca a. Hepatology. 2002 Oct;36(4 Pt 1):959-66. doi: 10.1053/jhep.2002.35442. Hepatology. 2002. PMID: 12297844 Clinical Trial.
Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured?
Ciancio A, Smedile A, Giordanino C, Colletta C, Croce G, Pozzi M, Cariti G, Macor A, Biglino A, Di Napoli A, Tappero GF, Andreoni M, Manca A, Prandi G, Calleri G, Orsi PG, Ciccone G, Rizzetto M, Saracco G; North West Italian Hepatologic Group. Ciancio A, et al. Among authors: manca a. Am J Gastroenterol. 2006 Aug;101(8):1811-6. doi: 10.1111/j.1572-0241.2006.00669.x. Epub 2006 Jun 16. Am J Gastroenterol. 2006. PMID: 16780556 Clinical Trial.
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study.
Bergamaschi G, Castiglione F, D'Incà R, Astegiano M, Fries W, Milla M, Ciacci C, Rizzello F, Saibeni S, Ciccocioppo R, Orlando A, Bossa F, Principi M, Vernia P, Ricci C, Scribano ML, Bodini G, Mazzucco D, Bassotti G, Riegler G, Buda A, Neri M, Caprioli F, Monica F, Manca A, Villa E, Fiorino G, Comberlato M, Aronico N, Della Corte C, Caccaro R, Gionchetti P, Giuffrida P, Iovino P, Lenti MV, Mengoli C, Pellegrini L, Pieraccini A, Ribaldone D, Testa A, Ubezio C, Viola A, Vecchi M, Klersy C, Di Sabatino A. Bergamaschi G, et al. Among authors: manca a. Inflamm Bowel Dis. 2023 Jan 5;29(1):76-84. doi: 10.1093/ibd/izac054. Inflamm Bowel Dis. 2023. PMID: 35366312
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use.
Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Annese V, Colombo E, Stefanelli T, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M. Danese S, et al. Among authors: manca a. Inflamm Bowel Dis. 2008 Aug;14(8):1168-70. doi: 10.1002/ibd.20426. Inflamm Bowel Dis. 2008. PMID: 18357580 Clinical Trial. No abstract available.
500 results